133.15
price up icon1.72%   2.25
pre-market  プレマーケット:  133.04   -0.11   -0.08%
loading
前日終値:
$130.90
開ける:
$131.18
24時間の取引高:
1.21M
Relative Volume:
1.05
時価総額:
$13.36B
収益:
$2.86B
当期純損益:
$478.60M
株価収益率:
28.53
EPS:
4.6676
ネットキャッシュフロー:
$748.70M
1週間 パフォーマンス:
+0.45%
1か月 パフォーマンス:
+3.92%
6か月 パフォーマンス:
-4.26%
1年 パフォーマンス:
+52.10%
1日の値動き範囲:
Value
$128.90
$133.20
1週間の範囲:
Value
$125.31
$134.20
52週間の値動き範囲:
Value
$84.23
$160.18

Neurocrine Biosciences Inc Stock (NBIX) Company Profile

Name
名前
Neurocrine Biosciences Inc
Name
セクター
Healthcare (1111)
Name
電話
(858) 617-7600
Name
住所
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Name
職員
2,000
Name
Twitter
Name
次回の収益日
2024-10-30
Name
最新のSEC提出書
Name
NBIX's Discussions on Twitter

Compare NBIX vs TAK, ZTS, HLN, TEVA, UTHR

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
NBIX icon
NBIX
Neurocrine Biosciences Inc
133.15 13.36B 2.86B 478.60M 748.70M 4.6676
TAK icon
TAK
Takeda Pharmaceutical Co Adr
18.66 58.95B 29.85B 776.90M 4.35B 0.2408
ZTS icon
ZTS
Zoetis Inc
119.75 50.55B 9.47B 2.67B 2.28B 6.0218
HLN icon
HLN
Haleon Plc Adr
9.97 44.44B 14.54B 2.22B 2.58B 0.4871
TEVA icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
30.52 35.54B 17.41B 1.43B 1.00B 1.2182
UTHR icon
UTHR
United Therapeutics Corp
581.69 25.49B 3.18B 1.33B 1.04B 27.90

Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-02-24 開始されました Wolfe Research Outperform
2026-01-08 ダウングレード Morgan Stanley Overweight → Equal-Weight
2025-10-21 開始されました Citigroup Buy
2025-07-21 開始されました Truist Buy
2025-07-10 開始されました Goldman Buy
2025-04-15 アップグレード Needham Hold → Buy
2025-04-14 アップグレード RBC Capital Mkts Sector Perform → Outperform
2025-02-11 開始されました Deutsche Bank Hold
2024-10-10 再開されました Raymond James Outperform
2024-08-29 アップグレード Piper Sandler Neutral → Overweight
2024-04-24 アップグレード Wells Fargo Equal Weight → Overweight
2023-12-13 再開されました Citigroup Neutral
2023-12-12 開始されました Deutsche Bank Buy
2023-10-24 再開されました Cantor Fitzgerald Overweight
2023-08-21 繰り返されました Mizuho Neutral
2023-07-24 アップグレード SVB Securities Market Perform → Outperform
2023-07-06 アップグレード BMO Capital Markets Underperform → Market Perform
2023-05-04 アップグレード Guggenheim Neutral → Buy
2023-03-30 アップグレード Canaccord Genuity Hold → Buy
2023-03-03 アップグレード Evercore ISI In-line → Outperform
2023-02-03 アップグレード Morgan Stanley Equal-Weight → Overweight
2022-11-14 ダウングレード Evercore ISI Outperform → In-line
2022-10-11 開始されました UBS Buy
2022-09-26 開始されました Wells Fargo Equal Weight
2022-06-06 再開されました Jefferies Buy
2022-03-03 ダウングレード Piper Sandler Overweight → Neutral
2022-02-25 アップグレード Goldman Neutral → Buy
2022-01-18 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2021-11-19 開始されました BMO Capital Markets Underperform
2021-11-17 アップグレード JP Morgan Neutral → Overweight
2021-10-14 ダウングレード Morgan Stanley Overweight → Equal-Weight
2021-09-23 再開されました Needham Hold
2021-08-06 ダウングレード Canaccord Genuity Buy → Hold
2021-05-18 再開されました Goldman Neutral
2021-05-06 アップグレード Barclays Equal Weight → Overweight
2021-02-02 開始されました Raymond James Outperform
2020-09-30 開始されました The Benchmark Company Hold
2020-08-04 ダウングレード JP Morgan Overweight → Neutral
2020-06-29 ダウングレード Goldman Buy → Neutral
2020-06-09 開始されました Wedbush Outperform
2020-03-06 開始されました Citigroup Buy
2020-02-27 開始されました Barclays Equal Weight
2020-02-24 開始されました William Blair Outperform
2020-02-06 開始されました Mizuho Neutral
2020-02-05 繰り返されました H.C. Wainwright Buy
2019-12-13 ダウングレード Credit Suisse Outperform → Neutral
2019-08-07 開始されました RBC Capital Mkts Outperform
2019-07-16 開始されました Oppenheimer Outperform
2019-06-05 開始されました Guggenheim Neutral
2019-05-21 開始されました Credit Suisse Outperform
2019-04-22 アップグレード JP Morgan Neutral → Overweight
2019-04-12 開始されました Evercore ISI Outperform
2019-02-06 繰り返されました BofA/Merrill Buy
2019-01-23 ダウングレード JP Morgan Overweight → Neutral
2018-12-13 開始されました Goldman Buy
2018-11-21 開始されました Canaccord Genuity Buy
すべてを表示

Neurocrine Biosciences Inc (NBIX) 最新ニュース

pulisher
04:01 AM

Neurocrine Biosciences Inc (NASDAQ:NBIX) Emerges as a Top Affordable Growth Stock - ChartMill

04:01 AM
pulisher
12:25 PM

Soleno Therapeutics rallies on report of $2.5B Neurocrine buyout talks - MSN

12:25 PM
pulisher
Apr 08, 2026

Soleno Therapeutics Stock Rallies 56.4% in a Week: Here's Why - TradingView

Apr 08, 2026
pulisher
Apr 08, 2026

Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Bausch + Lomb Corporation (BLCO) and UnitedHealth (UNH) - The Globe and Mail

Apr 08, 2026
pulisher
Apr 08, 2026

Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Guardant Health (GH) and Compass Therapeutics (CMPX) - The Globe and Mail

Apr 08, 2026
pulisher
Apr 08, 2026

NBIX SEC FilingsNeurocrine Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Apr 08, 2026
pulisher
Apr 08, 2026

Neurocrine Biosciences Weighs Soleno Deal To Broaden CNS Portfolio - Sahm

Apr 08, 2026
pulisher
Apr 08, 2026

Momentum Shift: What hedge funds are buying Neurocrine Biosciences IncMarket Activity Recap & Verified Technical Trade Signals - baoquankhu1.vn

Apr 08, 2026
pulisher
Apr 07, 2026

Assessing Neurocrine Biosciences (NBIX) Valuation As Long Term Returns Outpace A Richer Earnings Multiple - Yahoo Finance

Apr 07, 2026
pulisher
Apr 07, 2026

Soleno withdraws EU rare disease drug application ahead of Neurocrine takeover - The Economic Times

Apr 07, 2026
pulisher
Apr 07, 2026

RBC Capital Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Cuts Target Price to $176 - Moomoo

Apr 07, 2026
pulisher
Apr 07, 2026

A Quick Look at Today's Ratings for Neurocrine Biosciences(NBIX.US), With a Forecast Between $140 to $242 - Moomoo

Apr 07, 2026
pulisher
Apr 07, 2026

Neurocrine Soleno Deal Adds Vykat XR And Alters Valuation Story - Yahoo Finance

Apr 07, 2026
pulisher
Apr 07, 2026

Neurocrine Biosciences (NBIX): A New Era in Neuroscience and Endocrinology - The Chronicle-Journal

Apr 07, 2026
pulisher
Apr 07, 2026

Neurocrine Biosciences (NASDAQ:NBIX) Given New $166.00 Price Target at Wedbush - MarketBeat

Apr 07, 2026
pulisher
Apr 07, 2026

Soleno Therapeutics Pulls Europe Drug Filing After $2.9 Billion Neurocrine Deal - TechStock²

Apr 07, 2026
pulisher
Apr 07, 2026

RBC Capital Adjusts Neurocrine Biosciences PT to $176 From $177, Maintains Outperform Rating - marketscreener.com

Apr 07, 2026
pulisher
Apr 07, 2026

Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion | Vykat XRNews and Statistics - IndexBox

Apr 07, 2026
pulisher
Apr 07, 2026

Robinhood Asset Management LLC Makes New $5.72 Million Investment in Neurocrine Biosciences, Inc. $NBIX - MarketBeat

Apr 07, 2026
pulisher
Apr 07, 2026

Neurocrine to acquire Soleno in $2.9bn transaction - Pharmaceutical Technology

Apr 07, 2026
pulisher
Apr 07, 2026

Neurocrine expands portfolio with buy of Soleno Therapeutics - The Pharma Letter

Apr 07, 2026
pulisher
Apr 07, 2026

TD Cowen downgrades Soleno Therapeutics stock on Neurocrine acquisition By Investing.com - Investing.com India

Apr 07, 2026
pulisher
Apr 07, 2026

TD Cowen downgrades Soleno Therapeutics stock on Neurocrine acquisition - Investing.com

Apr 07, 2026
pulisher
Apr 07, 2026

Neurocrine to acquire Soleno in multi-billion dollar deal - marketscreener.com

Apr 07, 2026
pulisher
Apr 07, 2026

Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio - Bitget

Apr 07, 2026
pulisher
Apr 07, 2026

Neurocrine Scoops Up Hunger-Drug Maker in Latest Multi-Billion-Dollar Pharma Deal - Yahoo Finance

Apr 07, 2026
pulisher
Apr 06, 2026

Neurocrine to buy Soleno Therapeutics for $53/share in cash - MSN

Apr 06, 2026
pulisher
Apr 06, 2026

Neurocrine-Soleno deal garners Wall Street praise — analyst applauds business development acumen - MSN

Apr 06, 2026
pulisher
Apr 06, 2026

Neurocrine Agrees $2.9 Billion Soleno Deal At 34% Premium - GuruFocus

Apr 06, 2026
pulisher
Apr 06, 2026

Soleno Therapeutics Stock Jumps After Neurocrine’s $2.9 Billion Bet on Vykat XR - TechStock²

Apr 06, 2026
pulisher
Apr 06, 2026

Neurocrine to seek Soleno (NASDAQ: SLNO) shares via tender offer - Stock Titan

Apr 06, 2026
pulisher
Apr 06, 2026

Neurocrine Biosciences to buy Soleno Therapeutics in $2.9B deal - axios.com

Apr 06, 2026
pulisher
Apr 06, 2026

Neurocrine’s $2.9B Soleno Buyout Brings What Could Become Its Next Blockbuster Drug - MedCity News

Apr 06, 2026
pulisher
Apr 06, 2026

Five More Things To Know About Neurocrine’s $2.9bn Bid For Soleno - Citeline News & Insights

Apr 06, 2026
pulisher
Apr 06, 2026

This Bay Area company's stock fell to less than $1, but one decision led it to a $53-a-share acquisition - The Business Journals

Apr 06, 2026
pulisher
Apr 06, 2026

Neurocrine to seek all Soleno shares in tender offer (NASDAQ: SLNO) - Stock Titan

Apr 06, 2026
pulisher
Apr 06, 2026

Wedbush raises Neurocrine Bio stock price target on acquisition By Investing.com - Investing.com India

Apr 06, 2026
pulisher
Apr 06, 2026

Why Soleno Therapeutics Stock Rocketed Higher on Monday - The Motley Fool

Apr 06, 2026
pulisher
Apr 06, 2026

Neurocrine expands into metabolic diseases with $2.9 billion Soleno buyout - WHTC

Apr 06, 2026
pulisher
Apr 06, 2026

Key facts: Neurocrine buys VYKAT XR for $2.9B; adds rare‑disease asset - TradingView

Apr 06, 2026
pulisher
Apr 06, 2026

Oppenheimer raises Neurocrine Biosciences price target on acquisition By Investing.com - Investing.com Canada

Apr 06, 2026
pulisher
Apr 06, 2026

Oppenheimer Adjusts Neurocrine Biosciences Price Target to $220 From $192, Maintains Outperform Rating - marketscreener.com

Apr 06, 2026
pulisher
Apr 06, 2026

Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9B to Expand Rare Disease Portfolio - Oncodaily

Apr 06, 2026
pulisher
Apr 06, 2026

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. - Barron's

Apr 06, 2026
pulisher
Apr 06, 2026

Baird reiterates Neurocrine Bio stock rating on acquisition potential - investing.com

Apr 06, 2026
pulisher
Apr 06, 2026

Baird reiterates Neurocrine Bio stock rating on acquisition potential By Investing.com - Investing.com Australia

Apr 06, 2026
pulisher
Apr 06, 2026

Cooley, Wilson Sonsini Steer Neurocrine's $2.9B Soleno Buy - Law360

Apr 06, 2026
pulisher
Apr 06, 2026

Neurocrine Biosciences to Acquire Soleno Therapeutics for $2.9B - National Today

Apr 06, 2026
pulisher
Apr 06, 2026

American Neurocrine Biosciences acquires Soleno Therapeutics for $2.9 billion - AKM.RU

Apr 06, 2026
pulisher
Apr 06, 2026

Soleno Stock Soars on $2.9 Billion Neurocrine Buyout. Its Hunger Drug Is a Different Weight-Loss Play. - Barron's

Apr 06, 2026
pulisher
Apr 06, 2026

Soleno Therapeutics Soars as Neurocrine Unveils $2.9B All-Cash Buyout at $53 a Share - Yahoo Finance

Apr 06, 2026

Neurocrine Biosciences Inc (NBIX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
RGC RGC
$28.88
price up icon 3.66%
$23.60
price up icon 3.51%
RDY RDY
$13.24
price up icon 2.24%
$13.57
price up icon 3.12%
$581.69
price up icon 2.83%
大文字化:     |  ボリューム (24 時間):